Compare Merck & Co., Inc. (MRK) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Phillips 66 — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Merck & Co., Inc. is far larger — about 3.1× Phillips 66's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Phillips 66 for 62 Days on average.
| MRK | PSX | |
|---|---|---|
Market Cap | $351.28B | $112.36B |
Volume | 7,969,665 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $156.43 | $281.60 |
52-Week Low | $82.49 | $126.76 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $398.04B | $128.83B |
Dividend Yield | 2.39% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Phillips 66 (PSX) trades at $281.60, up 3.67% over the past 24 hours and near its 52-week high, supported by bullish technical indicators and strong earnings beats in recent quarters. The company's fundamentals show solid profitability with a 4.66% net income margin and 24.02% ROE, while valuation ratios like a P/E of 16.07 and P/S of 0.75 appear reasonable. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
The outlook for PSX is positive, driven by elevated refining crack spreads and debt-reduction progress, but risks include volatile energy prices and potential policy impacts on diesel exports. Analyst consensus leans bullish with a $279 price target, offering moderate upside from current levels amid robust institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
